Advertisement
Advertisement
U.S. markets open in 3 hours 23 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Instil Bio, Inc. (TIL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.250.00 (0.00%)
At close: 04:00PM EDT
5.09 -0.16 (-3.05%)
After hours: 04:09PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close5.25
Open5.20
Bid0.00 x 1300
Ask0.00 x 1800
Day's Range5.03 - 5.27
52 Week Range3.90 - 23.22
Volume172,278
Avg. Volume328,662
Market Cap680.894M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.45
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for TIL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Instil Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 03/26/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit

    DALLAS, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in an upcoming investor conference: Jefferies Cell and Genetic Medicine SummitCompany presentation and Q&A: Thursday, September 29, 2022 at 10:30 a.m. ET A live webcast, if recorded, of the presentati

  • GlobeNewswire

    Instil Bio to Present at Morgan Stanley Global Healthcare Conference

    DALLAS, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company management will participate in an upcoming investor conference: Morgan Stanley 20th Annual Global Healthcare ConferenceFireside Chat: Monday, September 12, 2022 at 2:50 p.m. ET A live webcast, if recorded, of each presentation c

  • GlobeNewswire

    Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

    DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer. Tim Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations, including at Genentech, Kite and most recently PACT Pharma

Advertisement
Advertisement